Announcements
- Royalty Pharma Declares Second Quarter 2024 Dividend
- Royalty Pharma to Present at TD Cowen’s 44th Annual Health Care Conference
- Royalty Pharma Reports Q4 and Full Year 2023 Results
- Royalty Pharma To Announce Fourth Quarter And Full Year 2023 Financial Results On February 15, 2024
- Royalty Pharma Announces Dividend Increase
- Royalty Pharma Highlights Accomplishments and Provides Business Update at 42nd Annual J.P. Morgan Healthcare Conference
- Royalty Pharma to Present at the Evercore ISI 6th Annual HealthCONx Conference
- Royalty Pharma and Teva Collaborate to Further Accelerate Olanzapine Lai Program
- Royalty Pharma Reports Third Quarter 2023 Results
- Royalty Pharma Announces Agreement to Purchase Up to $1.5 Billion of PTC Therapeutics’ Royalty on Evrysdi
More ▼
Key statistics
On Wednesday, Royalty Pharma PLC (RPD:DUS) closed at 25.82, 7.49% above its 52-week low of 24.02, set on Nov 22, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 25.53 |
---|---|
High | 25.83 |
Low | 25.51 |
Bid | 25.83 |
Offer | 26.09 |
Previous close | 25.99 |
Average volume | 96.22 |
---|---|
Shares outstanding | 597.43m |
Free float | 424.65m |
P/E (TTM) | 10.83 |
Market cap | 16.41bn USD |
EPS (TTM) | 2.54 USD |
Annual div (ADY) | 0.7797 EUR |
---|---|
Annual div yield (ADY) | 3.00% |
Div ex-date | Feb 15 2024 |
Div pay-date | Mar 15 2024 |
Data delayed at least 15 minutes, as of Apr 17 2024 18:31 BST.
More ▼